EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:43871 - fasudil
| Formula | C14H17N3O2S |
| Net Charge | 0 |
| Average Mass | 291.376 |
| Monoisotopic Mass | 291.10415 |
| SMILES | O=S(=O)(c1cccc2cnccc12)N1CCCNCC1 |
| InChI | InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2 |
| InChIKey | NGOGFTYYXHNFQH-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine. calcium channel blocker One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools. |
| Applications: | geroprotector Any compound that supports healthy aging, slows the biological aging process, or extends lifespan. nootropic agent Any compound that improves mental functions such as cognition, memory, intelligence, motivation, attention, and concentration. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. vasodilator agent A drug used to cause dilation of the blood vessels. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. neuroprotective agent Any compound that can be used for the treatment of neurodegenerative disorders. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| fasudil (CHEBI:43871) has role antihypertensive agent (CHEBI:35674) |
| fasudil (CHEBI:43871) has role calcium channel blocker (CHEBI:38215) |
| fasudil (CHEBI:43871) has role cardiovascular drug (CHEBI:35554) |
| fasudil (CHEBI:43871) has role EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor (CHEBI:50925) |
| fasudil (CHEBI:43871) has role geroprotector (CHEBI:176497) |
| fasudil (CHEBI:43871) has role neuroprotective agent (CHEBI:63726) |
| fasudil (CHEBI:43871) has role nootropic agent (CHEBI:66980) |
| fasudil (CHEBI:43871) has role vasodilator agent (CHEBI:35620) |
| fasudil (CHEBI:43871) is a N-sulfonyldiazepane (CHEBI:46946) |
| fasudil (CHEBI:43871) is a isoquinolines (CHEBI:24922) |
| fasudil (CHEBI:43871) is conjugate base of fasudil(1+) (CHEBI:180694) |
| Incoming Relation(s) |
| fasudil(1+) (CHEBI:180694) is conjugate acid of fasudil (CHEBI:43871) |
| IUPAC Name |
|---|
| 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline |
| INNs | Source |
|---|---|
| fasudil | WHO MedNet |
| fasudil | WHO MedNet |
| fasudil | WHO MedNet |
| fasudilum | WHO MedNet |
| Synonyms | Source |
|---|---|
| 1-(5-isoquinolinesulfonyl)homopiperazine | ChemIDplus |
| 5-[(hexahydro-1H-1,4-diazepin-1-yl)sulfonyl]isoquinoline | ChEBI |
| AT 877 | ChemIDplus |
| AT-877 | ChemIDplus |
| HA 1077 | ChemIDplus |
| HA-1077 | DrugCentral |
| Registry Numbers | Sources |
|---|---|
| CAS:103745-39-7 | ChemIDplus |
| Citations |
|---|